应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
HURA TuHURA Biosciences, Inc.
未开盘 02-10 16:00:00 EST
1.30
+0.49
+60.47%
盘后
1.52
+0.22
+16.92%
19:59 EST
最高
1.37
最低
0.8300
成交量
2,204万
今开
0.8400
昨收
0.8101
日振幅
66.66%
总市值
7,894万
流通市值
7,057万
总股本
6,072万
成交额
2,583万
换手率
40.61%
流通股本
5,429万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Tuhura Biosciences, Inc.盘中异动 快速下挫5.55%
市场透视 · 02-03
Tuhura Biosciences, Inc.盘中异动 快速下挫5.55%
TuHURA Biosciences获FDA孤儿药认定 IFX-2.0有望治疗IIb至IV期皮肤黑色素瘤
美股速递 · 02-02
TuHURA Biosciences获FDA孤儿药认定 IFX-2.0有望治疗IIb至IV期皮肤黑色素瘤
Tuhura Biosciences, Inc.盘中异动 股价大涨6.74%
市场透视 · 01-08
Tuhura Biosciences, Inc.盘中异动 股价大涨6.74%
Tuhura Biosciences发布Kintara的应急价值权(CVR),因Kintara的Rem-001达到了主要安全目标,实现合同里程碑
美股速递 · 2025-12-15
Tuhura Biosciences发布Kintara的应急价值权(CVR),因Kintara的Rem-001达到了主要安全目标,实现合同里程碑
Tuhura Biosciences展示数据显示,Delta阿片受体(Dor)作为克服对免疫检查点抑制剂获得性耐药的新靶点,亮相第57届ASH年会暨博览会
美股速递 · 2025-12-08
Tuhura Biosciences展示数据显示,Delta阿片受体(Dor)作为克服对免疫检查点抑制剂获得性耐药的新靶点,亮相第57届ASH年会暨博览会
Tuhura Biosciences Inc申请最高2.5亿美元的混合货架注册
投资观察 · 2025-11-20
Tuhura Biosciences Inc申请最高2.5亿美元的混合货架注册
Tuhura Biosciences Inc:与H.C. Wainwright签订Atm协议以出售高达5000万美元的普通股
美股速递 · 2025-11-04
Tuhura Biosciences Inc:与H.C. Wainwright签订Atm协议以出售高达5000万美元的普通股
TuHURA Biosciences(HURA.US)获HC Wainwright & Co.首次覆盖,给予买入评级, 目标价13.00美元。
金融界 · 2025-03-03
TuHURA Biosciences(HURA.US)获HC Wainwright & Co.首次覆盖,给予买入评级, 目标价13.00美元。
暂无数据
公司概况
公司名称:
TuHURA Biosciences, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
TuHURA Biosciences, Inc.是一家内华达州公司,成立于2009年6月24日,名称为Berry Only,Inc。该公司是一家临床阶段的生物制药公司。Kintara致力于为医疗需求未得到满足的患者开发新型癌症疗法。Kintara公司正在开发两种晚期疗法,以降低风险,满足明确的未满足的医疗需求。这两个项目分别是VAL-083治疗胶质母细胞瘤(GBM)和REM-001治疗皮肤转移性乳腺癌(CMBC)。
发行价格:
--
{"stockData":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":1.3,"timestamp":1770757200000,"preClose":0.8101,"halted":0,"volume":22044872,"hourTrading":{"tag":"盘后","latestPrice":1.52,"preClose":1.3,"latestTime":"19:59 EST","volume":2781308,"amount":4093445.5381,"timestamp":1770771589798,"change":0.22,"changeRate":0.169231,"amplitude":0.307692},"delay":0,"changeRate":0.6047401555363535,"floatShares":54286373,"shares":60720508,"eps":-0.662671,"marketStatus":"未开盘","change":0.4899,"latestTime":"02-10 16:00:00 EST","open":0.84,"high":1.37,"low":0.83,"amount":25827104.075578403,"amplitude":0.666584,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.662671,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770800400000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":0.8101,"preHourTrading":{"tag":"盘前","latestPrice":0.83,"preClose":0.8101,"latestTime":"09:29 EST","volume":101654,"amount":87948.5553597,"timestamp":1770733784268,"change":0.0199,"changeRate":0.024565,"amplitude":0.143686},"postHourTrading":{"tag":"盘后","latestPrice":1.52,"preClose":1.3,"latestTime":"19:59 EST","volume":2781308,"amount":4093445.5381,"timestamp":1770771589798,"change":0.22,"changeRate":0.169231,"amplitude":0.307692},"volumeRatio":10.114378},"requestUrl":"/m/hq/s/HURA/tweets","defaultTab":"tweets","newsList":[{"id":"2608977807","title":"Tuhura Biosciences, Inc.盘中异动 快速下挫5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608977807","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608977807?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:33","pubTimestamp":1770129200,"startTime":"0","endTime":"0","summary":"北京时间2026年02月03日22时33分,Tuhura Biosciences, Inc.股票出现波动,股价快速跳水5.55%。Tuhura Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.36%。Tuhura Biosciences, Inc.公司简介:TuHURA Biosciences Inc 是一家处于 3 期注册阶段的免疫肿瘤公司,致力于开发克服癌症免疫治疗耐药性的新技术。该公司的个性化癌症候选疫苗 IFx-2.0 旨在克服对检查点抑制剂的主要耐药性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020322332197a4b21c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020322332197a4b21c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"1169978766","title":"TuHURA Biosciences获FDA孤儿药认定 IFX-2.0有望治疗IIb至IV期皮肤黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1169978766","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169978766?lang=zh_cn&edition=full","pubTime":"2026-02-02 20:45","pubTimestamp":1770036316,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc. (以下简称TuHURA) 宣布,其研发的候选药物IFX-2.0已获得美国食品药品监督管理局(FDA)授予的孤儿药资格认定,适应症为IIb期至IV期皮肤黑色素瘤。\n孤儿药认定旨在鼓励针对罕见病的新药研发。获得该认定意味着IFX-2.0在针对这一特定阶段的黑色素瘤治疗方面,有望在药物开发及后续商业化进程中享受一系列政策支持,包括临床试验费用税收抵免、FDA用户费减免以及药物获批后七年的市场独占权。\n此次认定标志着IFX-2.0在治疗晚期皮肤黑色素瘤的研发道路上迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2601937463","title":"Tuhura Biosciences, Inc.盘中异动 股价大涨6.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601937463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601937463?lang=zh_cn&edition=full","pubTime":"2026-01-08 04:02","pubTimestamp":1767816142,"startTime":"0","endTime":"0","summary":"北京时间2026年01月08日04时02分,Tuhura Biosciences, Inc.股票出现异动,股价急速上涨6.74%。Tuhura Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为3.15%。其相关个股中,Revolution Medicines Inc C/Wts 17/12/2026 、Lexaria Bioscience Corp C/Wts 14/01/2026 、Erasca, Inc.涨幅较大,Cardio Diagnostics Holdings Inc.、Pmgc Holdings Inc.、Aspire Biopharma Holdings, Inc.较为活跃,换手率分别为1093.70%、682.96%、351.70%,振幅较大的相关个股有Revolution Medicines Inc C/Wts 17/12/2026 、Erasca, Inc.、Moolec Science Sa C/Wts 30/01/2028,振幅分别为202.13%、67.49%、50.85%。Tuhura Biosciences, Inc.公司简介:TuHURA Biosciences Inc 是一家处于 3 期注册阶段的免疫肿瘤公司,致力于开发克服癌症免疫治疗耐药性的新技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108040222a6ffe016&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108040222a6ffe016&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"1150512948","title":"Tuhura Biosciences发布Kintara的应急价值权(CVR),因Kintara的Rem-001达到了主要安全目标,实现合同里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1150512948","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150512948?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:50","pubTimestamp":1765803053,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences发布Kintara的应急价值权(CVR),因Kintara的Rem-001达到了主要安全目标,实现合同里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"1183862465","title":"Tuhura Biosciences展示数据显示,Delta阿片受体(Dor)作为克服对免疫检查点抑制剂获得性耐药的新靶点,亮相第57届ASH年会暨博览会","url":"https://stock-news.laohu8.com/highlight/detail?id=1183862465","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183862465?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:51","pubTimestamp":1765198302,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences展示数据显示,Delta阿片受体(Dor)作为克服对免疫检查点抑制剂获得性耐药的新靶点,亮相第57届ASH年会暨博览会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"1115688327","title":"Tuhura Biosciences Inc申请最高2.5亿美元的混合货架注册","url":"https://stock-news.laohu8.com/highlight/detail?id=1115688327","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115688327?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:31","pubTimestamp":1763569873,"startTime":"0","endTime":"0","summary":"11月4日 - TuHURA Biosciences Inc宣布,已向SEC提交申请,计划进行最高达2.5亿美元的混合货架注册。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"1152480810","title":"Tuhura Biosciences Inc:与H.C. Wainwright签订Atm协议以出售高达5000万美元的普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1152480810","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152480810?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:23","pubTimestamp":1762259005,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences Inc:与H.C. Wainwright签订Atm协议以出售高达5000万美元的普通股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2516049635","title":"TuHURA Biosciences(HURA.US)获HC Wainwright & Co.首次覆盖,给予买入评级, 目标价13.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516049635","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516049635?lang=zh_cn&edition=full","pubTime":"2025-03-03 21:20","pubTimestamp":1741008040,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences(HURA.US)获HC Wainwright & Co.首次覆盖,给予买入评级, 目标价13.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03212048493051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HURA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintara.com","stockEarnings":[{"period":"1week","weight":1.7849},{"period":"1month","weight":0.7248},{"period":"3month","weight":-0.417},{"period":"6month","weight":-0.529},{"period":"1year","weight":-0.7072},{"period":"ytd","weight":0.718}],"compareEarnings":[{"period":"1week","weight":0.0038},{"period":"1month","weight":-0.0028},{"period":"3month","weight":0.0128},{"period":"6month","weight":0.0731},{"period":"1year","weight":0.1443},{"period":"ytd","weight":0.015}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"TuHURA Biosciences, Inc.是一家内华达州公司,成立于2009年6月24日,名称为Berry Only,Inc。该公司是一家临床阶段的生物制药公司。Kintara致力于为医疗需求未得到满足的患者开发新型癌症疗法。Kintara公司正在开发两种晚期疗法,以降低风险,满足明确的未满足的医疗需求。这两个项目分别是VAL-083治疗胶质母细胞瘤(GBM)和REM-001治疗皮肤转移性乳腺癌(CMBC)。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.054973},{"month":2,"riseRate":0.2,"avgChangeRate":0.007425},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.000318},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.030862},{"month":5,"riseRate":0.555556,"avgChangeRate":1.198143},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.040545},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.01467},{"month":8,"riseRate":0.5,"avgChangeRate":-0.086193},{"month":9,"riseRate":0.3,"avgChangeRate":-0.103258},{"month":10,"riseRate":0.4,"avgChangeRate":-0.116072},{"month":11,"riseRate":0.4,"avgChangeRate":-0.068131},{"month":12,"riseRate":0.2,"avgChangeRate":-0.220735}],"exchange":"NASDAQ","name":"TuHURA Biosciences, Inc.","nameEN":"TuHURA Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TuHURA Biosciences, Inc.(HURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供TuHURA Biosciences, Inc.(HURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"TuHURA Biosciences, Inc.,HURA,TuHURA Biosciences, Inc.股票,TuHURA Biosciences, Inc.股票老虎,TuHURA Biosciences, Inc.股票老虎国际,TuHURA Biosciences, Inc.行情,TuHURA Biosciences, Inc.股票行情,TuHURA Biosciences, Inc.股价,TuHURA Biosciences, Inc.股市,TuHURA Biosciences, Inc.股票价格,TuHURA Biosciences, Inc.股票交易,TuHURA Biosciences, Inc.股票购买,TuHURA Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TuHURA Biosciences, Inc.(HURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供TuHURA Biosciences, Inc.(HURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}